Cencora Inc. stock eases after recent insider share sale

Published on 09/18/2026 at 15:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cencora Inc. stock recently traded around USD 318.54 on the New York Stock Exchange as of September 17, 2026, after a volatile session. A director share sale worth about USD 411,264 and elevated options volatility add nuance to the recent move.

Luftbild eines modernen Pharma-Lagerzentrums mit Lieferfahrzeugen und Verladedocks — Cencora Inc. betreibt US15135B1017 ein großes Pharmadistributionszentrum mit Lastwagen Gabelstaplern und täglicher Medikamentenlogistik, Illustration mit AI erstellt.

Cencora Inc. stock (ISIN US15135B1017) recently changed hands at around USD 318.54 on the New York Stock Exchange as of September 17, 2026, reflecting a pullback from recent highs after a volatile trading session in which the shares closed lower by about 2.8 percent compared with the prior day.

Insider sale adds to short term caution

According to StockTitan on September 17, 2026, Cencora director Lon R. Greenberg reported selling 1,280 shares of common stock on September 16, 2026 at USD 321.30 per share, for total proceeds of about USD 411,264.

This insider transaction came shortly after the stock had been quoted around USD 318.54 as of September 17, 2026, meaning the sale price stood modestly above the most recent reference level and underscores that management insiders are monetizing gains after a strong run.

Share price and volatility context

Per options data from OptionCharts, Cencora Inc. shares closed at USD 309.39 on the New York Stock Exchange on September 17, 2026, down USD 9.11 or 2.86 percent from the prior close, before rebounding in after hours trading to around USD 327.50, a move of 5.85 percent from the regular session close.

The same options overview shows that for options expiring on September 18, 2026, the average implied volatility for call options is 93.05 percent and 9.21 percent for put options, signaling that the options market is pricing in pronounced short term swings, particularly on the upside.

Recent earnings and margin profile

As summarized in a recent market overview, Cencora Inc. most recently reported earnings per share rising from USD 4.00 to USD 4.48 year over year in its latest fiscal period, while revenue increased by 5.1 percent over the same period and the company maintained a net margin below 1 percent, underlining the typical low margin profile of large pharmaceutical distribution businesses.

These figures indicate that while headline EPS growth of 12 percent from USD 4.00 to USD 4.48 outpaced revenue expansion of 5.1 percent, Cencora achieved this improvement mainly through operational leverage and efficiency gains rather than through outsized pricing power, given that the net margin remained under 1 percent.

Stock price snapshot

Cencora Inc. stock last traded around USD 318.54 on the New York Stock Exchange as of September 17, 2026, a level that sits between the regular session close of USD 309.39 and the after hours indication of USD 327.50, illustrating the elevated intraday volatility that has characterized trading around the latest insider sale and recent earnings data.